ALL-TRANS RETINOIC ACID IN REFRACTORY MECOM-REARRANGED ACUTE MYELOID LEUKEMIA WITH T(3;3)(Q21;Q26.2): A MOLECULARLY GUIDED THERAPEUTIC APPROACH
- 1Departamento de Imagens Médicas, Hematologia e Oncologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
- 2Hospital Felício Rocho, Belo Horizonte, MG, Brazil
Abstract
Background: Acute myeloid leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) is a rare, adverse-risk subtype characterized by enhancer hijacking involving the GATA2 regulatory region, resulting in aberrant MECOM/EVI1 activation and reduced GATA2 expression. This molecular configuration is associated with marked resistance to conventional chemotherapy and poor clinical outcomes. Preclinical evidence and limited clinical data have suggested that all-trans retinoic acid (ATRA) may partially overcome EVI1-associated differentiation blockade. We report a patient with refractory MECOM-rearranged AML in whom ATRA was incorporated into salvage therapy on a molecularly guided basis. Case report: A 58-year-old man was admitted with leukocytosis and thrombocytopenia. Molecular testing was negative for KMT2A::AFF1, BCR::ABL1, RUNX1::RUNX1T1, and CBFB::MYH11 rearrangements and for FLT3 and NPM1 mutations. Next-generation sequencing identified mutations in ASXL1, NRAS, GATA2 (variant allele frequency, 42%), and U2AF1. Conventional cytogenetics demonstrated 46,XY,t(3;3)(q21;q26.2)[20/20], establishing the diagnosis of AML with MECOM rearrangement and adverse-risk disease. The GATA2 variant was identified in the leukemic sample; its somatic versus germline origin was not established. Magnetic resonance imaging revealed a paravertebral T1–T2 soft-tissue mass and multiple vertebral lesions radiologically suspicious for extramedullary leukemic involvement. The patient did not respond to standard 7+3 induction chemotherapy. Salvage treatment with azacitidine plus venetoclax was subsequently initiated. Bone marrow assessment on day 21 demonstrated persistent disease with 11% blasts. During the second treatment cycle, ATRA was added after informed consent based on the biological rationale of targeting EVI1-associated transcriptional dysregulation. Venetoclax dosing was adjusted because of concomitant isavuconazole therapy for invasive fungal sinusitis. The patient remained clinically stable and was discharged with a plan to proceed to haploidentical allogeneic hematopoietic cell transplantation. Discussion and conclusion: AML with t(3;3)(q21;q26.2) is driven by repositioning of a GATA2 enhancer toward MECOM, leading to EVI1 overexpression and disruption of normal hematopoietic differentiation. This biology is associated with resistance to conventional chemotherapy and poor outcomes. The additional GATA2 variant identified at a variant allele frequency of 42% cannot be classified as somatic solely based on the absence of clinical manifestations associated with germline GATA2 deficiency and would require dedicated germline assessment for definitive characterization. Preclinical studies and a small clinical pilot study in EVI1-overexpressing AML provide preliminary support for investigating ATRA as a differentiation-based therapeutic strategy in this molecular context. In the present case, ATRA was incorporated into salvage therapy as a hypothesis-driven intervention rather than an established standard of care. This report highlights the potential value of comprehensive molecular characterization in guiding individualized therapeutic strategies for highly refractory MECOM-rearranged AML and supports further prospective evaluation of retinoid-based approaches in EVI1-driven disease.
Related
- Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
- [KMT2A-rearranged acute lymphoblastic leukemia with lineage switch following relapse: a case report and literature review].
- Ocular Myasthenia Gravis Unmasking Molecularly High-Risk but Clinically Indolent Chronic Lymphocytic Leukemia: A Case Report
- Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion
- Response to Venetoclax and Azacitidine in Induction-Refractory Adult Acute Myeloid Leukemia with UBTF Tandem Duplication and Associated Aberrant Splicing: A Case Report
BibTeX
@article{anastacio2026alltrans,
title = {{ALL-TRANS RETINOIC ACID IN REFRACTORY MECOM-REARRANGED ACUTE MYELOID LEUKEMIA WITH T(3;3)(Q21;Q26.2): A MOLECULARLY GUIDED THERAPEUTIC APPROACH}},
author = {Lucas De Barros ANASTACIO and Priscila Diniz Teixeira VASCONCELOS and Liege Lyra de PAULA and Julia Carolina LEITE and Italo Henrique Oliveira SANTANA and Elisa Dall'orto Figueiredo PIUZANA and Larrisa Mendes de SOUZA and Viviane Teixeira de SOUSA},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.107551},
url = {https://doi.org/10.1016/j.htct.2026.107551},
note = {CC BY},
}
RIS
TY - JOUR
TI - ALL-TRANS RETINOIC ACID IN REFRACTORY MECOM-REARRANGED ACUTE MYELOID LEUKEMIA WITH T(3;3)(Q21;Q26.2): A MOLECULARLY GUIDED THERAPEUTIC APPROACH
AU - Lucas De Barros ANASTACIO
AU - Priscila Diniz Teixeira VASCONCELOS
AU - Liege Lyra de PAULA
AU - Julia Carolina LEITE
AU - Italo Henrique Oliveira SANTANA
AU - Elisa Dall'orto Figueiredo PIUZANA
AU - Larrisa Mendes de SOUZA
AU - Viviane Teixeira de SOUSA
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.107551
UR - https://doi.org/10.1016/j.htct.2026.107551
AB - Background: Acute myeloid leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) is a rare, adverse-risk subtype characterized by enhancer hijacking involving the GATA2 regulatory region, resulting in aberrant MECOM/EVI1 activation and reduced GATA2 expression. This molecular configuration is associated with marked resistance to conventional chemotherapy and poor clinical outcomes. Preclinical evidence and limited clinical data have suggested that all-trans retinoic acid (ATRA) may partially overcome EVI1-associated differentiation blockade. We report a patient with refractory MECOM-rearranged AML in whom ATRA was incorporated into salvage therapy on a molecularly guided basis. Case report: A 58-year-old man was admitted with leukocytosis and thrombocytopenia. Molecular testing was negative for KMT2A::AFF1, BCR::ABL1, RUNX1::RUNX1T1, and CBFB::MYH11 rearrangements and for FLT3 and NPM1 mutations. Next-generation sequencing identified mutations in ASXL1, NRAS, GATA2 (variant allele frequency, 42%), and U2AF1. Conventional cytogenetics demonstrated 46,XY,t(3;3)(q21;q26.2)[20/20], establishing the diagnosis of AML with MECOM rearrangement and adverse-risk disease. The GATA2 variant was identified in the leukemic sample; its somatic versus germline origin was not established. Magnetic resonance imaging revealed a paravertebral T1–T2 soft-tissue mass and multiple vertebral lesions radiologically suspicious for extramedullary leukemic involvement. The patient did not respond to standard 7+3 induction chemotherapy. Salvage treatment with azacitidine plus venetoclax was subsequently initiated. Bone marrow assessment on day 21 demonstrated persistent disease with 11% blasts. During the second treatment cycle, ATRA was added after informed consent based on the biological rationale of targeting EVI1-associated transcriptional dysregulation. Venetoclax dosing was adjusted because of concomitant isavuconazole therapy for invasive fungal sinusitis. The patient remained clinically stable and was discharged with a plan to proceed to haploidentical allogeneic hematopoietic cell transplantation. Discussion and conclusion: AML with t(3;3)(q21;q26.2) is driven by repositioning of a GATA2 enhancer toward MECOM, leading to EVI1 overexpression and disruption of normal hematopoietic differentiation. This biology is associated with resistance to conventional chemotherapy and poor outcomes. The additional GATA2 variant identified at a variant allele frequency of 42% cannot be classified as somatic solely based on the absence of clinical manifestations associated with germline GATA2 deficiency and would require dedicated germline assessment for definitive characterization. Preclinical studies and a small clinical pilot study in EVI1-overexpressing AML provide preliminary support for investigating ATRA as a differentiation-based therapeutic strategy in this molecular context. In the present case, ATRA was incorporated into salvage therapy as a hypothesis-driven intervention rather than an established standard of care. This report highlights the potential value of comprehensive molecular characterization in guiding individualized therapeutic strategies for highly refractory MECOM-rearranged AML and supports further prospective evaluation of retinoid-based approaches in EVI1-driven disease.
SN - 2531-1379
SN - 2531-1387
ER -